Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gallia G Levy

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
The New England Journal of Medicine|November 25, 2017
Emicizumab Prophylaxis in Hemophilia A with InhibitorsJohannes Oldenburg, Gallia G Levy
Blood|March 19, 2005
ADAMTS13 turns 3Gallia G Levy, David G Motto, David Ginsburg
Mammalian Genome : Official Journal of the International Mammalian Genome Society|January 12, 2008
The endothelial-specific regulatory mutation, Mvwf1, is a common mouse founder alleleJill M Johnsen, Gallia G Levy, Randal J Westrick, et al.
Journal of Clinical Pharmacology|September 21, 2021
A Model-Based Framework to Inform the Dose Selection and Study Design of Emicizumab for Pediatric Patients With Hemophilia AKoichiro Yoneyama, Christophe Schmitt, Tiffany Chang, et al.
Journal of Thrombosis and Haemostasis : JTH|May 25, 2019
Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical programGallia G Levy, Elina Asikanius, Peter Kuebler, et al.
Blood|July 29, 2006
Enhanced VWF biosynthesis and elevated plasma VWF due to a natural variant in the murine Vwf geneHeidi L Lemmerhirt, Jordan A Shavit, Gallia G Levy, et al.
Clinical Pharmacokinetics|December 8, 2017
A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia AKoichiro Yoneyama, Christophe Schmitt, Naoki Kotani, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 29, 2022
Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 studyAnna Kiialainen, Markus Niggli, Christine L Kempton, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 5, 2002
Sialyltransferase ST3Gal-IV operates as a dominant modifier of hemostasis by concealing asialoglycoprotein receptor ligandsLesley G Ellies, David Ditto, Gallia G Levy, et al.
Thrombosis and Haemostasis|October 21, 2020
Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 StudyChristophe Schmitt, Joanne I Adamkewicz, Jin Xu, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
The New England Journal of Medicine|November 25, 2017
Emicizumab Prophylaxis in Hemophilia A with InhibitorsJohannes Oldenburg, Gallia G Levy
Blood|March 19, 2005
ADAMTS13 turns 3Gallia G Levy, David G Motto, David Ginsburg
Mammalian Genome : Official Journal of the International Mammalian Genome Society|January 12, 2008
The endothelial-specific regulatory mutation, Mvwf1, is a common mouse founder alleleJill M Johnsen, Gallia G Levy, Randal J Westrick, et al.
Journal of Clinical Pharmacology|September 21, 2021
A Model-Based Framework to Inform the Dose Selection and Study Design of Emicizumab for Pediatric Patients With Hemophilia AKoichiro Yoneyama, Christophe Schmitt, Tiffany Chang, et al.
Journal of Thrombosis and Haemostasis : JTH|May 25, 2019
Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical programGallia G Levy, Elina Asikanius, Peter Kuebler, et al.
Blood|July 29, 2006
Enhanced VWF biosynthesis and elevated plasma VWF due to a natural variant in the murine Vwf geneHeidi L Lemmerhirt, Jordan A Shavit, Gallia G Levy, et al.
Clinical Pharmacokinetics|December 8, 2017
A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia AKoichiro Yoneyama, Christophe Schmitt, Naoki Kotani, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 29, 2022
Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 studyAnna Kiialainen, Markus Niggli, Christine L Kempton, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 5, 2002
Sialyltransferase ST3Gal-IV operates as a dominant modifier of hemostasis by concealing asialoglycoprotein receptor ligandsLesley G Ellies, David Ditto, Gallia G Levy, et al.
Thrombosis and Haemostasis|October 21, 2020
Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 StudyChristophe Schmitt, Joanne I Adamkewicz, Jin Xu, et al.
Pageof 3